Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL — Stella

Home/Relapsed/Refractory Large B-Cell Lymphoma/Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

View on ClinicalTrials.gov

Recruiting

Back to Relapsed/Refractory Large B-Cell Lymphoma trials

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Safety & dosing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~89 participants

Started

May 2024

Primary completion

December 2026

Age range

18 Years and older

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.